Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 8, Issue 4
February 27 2024
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Maybe you can’t drive this CAR?
Benjamin A. Derman
View Articletitled, Maybe you can’t drive this CAR?
Bridging therapy before axi-cel for lymphoma
Clinical Trials & Observations
Safia Belbachir,Duncan Purtill
View Articletitled, Bridging therapy before axi-cel for lymphoma

ADVANCES VIEWPOINT

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help
Kevin J. Curran,Sarah Nikiforow,Carlos Bachier,Yen-Michael Hsu,David Maloney,Marcela V. Maus,Philip McCarthy,David Porter,Patricia Shi,Elizabeth J. Shpall,Basem William,Kara Wacker,Phyllis Warkentin,Helen E. Heslop
View Articletitled, A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help

SYSTEMATIC REVIEW

Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs
Clinical Trials & Observations
Connor Prosty,Khaled Katergi,Alex Nguyen,Owen Dan Luo,Mark Sorin,Vladimir Cherniak,Michael Sebag,Koray Demir,Emily G. McDonald,Todd C. Lee,Matthew P. Cheng
View Articletitled, Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Clinical Trials & Observations
Inhye E. Ahn,Danielle M. Brander,Yue Ren,Yinglu Zhou,Svitlana Tyekucheva,Heather A. Walker,Robert Black,Josie Montegaard,Alvaro Alencar,Leyla Shune,Mohammad Omaira,Caron A. Jacobson,Philippe Armand,Samuel Y. Ng,Jennifer Crombie,David C. Fisher,Ann S. LaCasce,Jon Arnason,Ephraim P. Hochberg,Ronald W. Takvorian,Jeremy S. Abramson,Jennifer R. Brown,Matthew S. Davids
View Articletitled, Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Supplemental data
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Clinical Trials & Observations
Tycel J. Phillips,Abraham Avigdor,Ronit Gurion,Caterina Patti,Paolo Corradini,Monica Tani,Amitkumar Mehta,Izidore S. Lossos,Pier Luigi Zinzani,Catherine Thieblemont,Wojciech Jurczak,Fred Zheng,Erica Rappold,Wanying Zhao,Ping Jiang,Peter Johnson
View Articletitled, A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Supplemental data
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
Clinical Trials & Observations
Rohan Shotton,Rachel Broadbent,Alia Alchawaf,Mohamed Bakri Mohamed,Adam Gibb,Nicolás Martinez-Calle,Christopher P. Fox,Mark Bishton,Alexandra Pender,Mary Gleeson,David Cunningham,Andrew Davies,Sina Yadollahi,Toby A. Eyre,Graham Collins,Faouzi Djebbari,Shireen Kassam,Paula Garland,Emily Watts,Wendy Osborne,William Townsend,Rachael Pocock,Matthew J. Ahearne,Fiona Miall,Xin Wang,Kim M. Linton
View Articletitled, Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
Supplemental data
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
Clinical Trials & Observations
Nicholas J. Short,Elias Jabbour,Nitin Jain,Jayastu Senapati,Lewis Nasr,Fadi G. Haddad,Zhenhua Li,Yu-Chih Hsiao,Jun J. Yang,Naveen Pemmaraju,Maro Ohanian,William G. Wierda,Guillermo Montalban-Bravo,Gautam Borthakur,Lina Han,Lianchun Xiao,Xuelin Huang,Regina Abramova,Min Zhao,Rebecca Garris,Marina Konopleva,Farhad Ravandi,Hagop Kantarjian
View Articletitled, A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
Supplemental data
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
Clinical Trials & Observations
Romit Bhattacharya,Md Mesbah Uddin,Aniruddh P. Patel,Abhishek Niroula,Phoebe Finneran,Rachel Bernardo,Kathleen V. Fitch,Michael T. Lu,Gerald S. Bloomfield,Carlos Malvestutto,Judy A. Aberg,Carl J. Fichtenbaum,Whitney Hornsby,Heather J. Ribaudo,Peter Libby,Benjamin L. Ebert,Markella V. Zanni,Pamela S. Douglas,Steven K. Grinspoon,Pradeep Natarajan
View Articletitled, Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
Supplemental data
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
Clinical Trials & Observations
Jacqueline S. Garcia,Haesook T. Kim,H. Moses Murdock,Michela Ansuinelli,Jennifer Brock,Corey S. Cutler,Mahasweta Gooptu,Vincent T. Ho,John Koreth,Sarah Nikiforow,Rizwan Romee,Roman Shapiro,Daniel J. DeAngelo,Richard M. Stone,Denbaa Bat-Erdene,Jeremy Ryan,Manuel E. Contreras,Geoffrey Fell,Anthony Letai,Jerome Ritz,R. Coleman Lindsley,Robert J. Soiffer,Joseph H. Antin
View Articletitled, Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
Supplemental data
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
Clinical Trials & Observations
Michael D. Jain,Miriam T. Jacobs,Feng Gao,Loretta J. Nastoupil,Jay Y. Spiegel,Yi Lin,Saurabh Dahiya,Matthew Lunning,Lazaros Lekakis,Patrick Reagan,Olalekan Oluwole,Joseph McGuirk,Abhinav Deol,Alison R. Sehgal,Andre Goy,Brian T. Hill,Charalambos Andreadis,Javier Munoz,Julio C Chavez,N. Nora Bennani,Aaron P. Rapoport,Julie M. Vose,David Miklos,Sattva S. Neelapu,Frederick L. Locke,Armin Ghobadi
View Articletitled, Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
Supplemental data
Bridging therapy before axi-cel for lymphoma
Clinical Trials & Observations
Safia Belbachir,Duncan Purtill
View Articletitled, Bridging therapy before axi-cel for lymphoma

HEMATOPOIESIS AND STEM CELLS

Choosing the right mouse model: comparison of humanized NSG and NBSGW mice for in vivo HSC gene therapy
Seunga Choo,Carl B. Wolf,Heather M. Mack,Mitchell J. Egan,Hans-Peter Kiem,Stefan Radtke
View Articletitled, Choosing the right mouse model: comparison of humanized NSG and NBSGW mice for in vivo HSC gene therapy
Supplemental data

LYMPHOID NEOPLASIA

MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study
Chiara Pagani,Chiara Rusconi,Alessia Dalla Pria,Emanuele Ravano,Philipp Schommers,Mariana Bastos-Oreiro,Luisa Verga,Guido Gini,Michele Spina,Luca Arcaini,Sara Steffanoni,Davide Dalu,Lara Crucitti,Luisa Lorenzi,Piera Balzarini,Chiara Cattaneo,Lucia Bongiovanni,Andreas Rosenwald,Fabio Facchetti,Mark Bower,Andrés J. M. Ferreri,Giuseppe Rossi,Alessandra Tucci,Alessandro Re
View Articletitled, MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study

MYELOID NEOPLASIA

High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer
Aaron J. Stonestrom,Kamal N. Menghrajani,Sean M. Devlin,Sebastià Franch-Expósito,Ryan N. Ptashkin,Swara Y. Patel,Barbara Spitzer,Xiaodi Wu,Justin Jee,Pablo Sánchez Vela,Jennifer H. Milbank,Ronak H. Shah,Abhinita S. Mohanty,A. Rose Brannon,Wenbin Xiao,Michael F. Berger,Simon Mantha,Ross L. Levine
View Articletitled, High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer
Supplemental data
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Clinical Trials & Observations
Alex Bataller,Alexandre Bazinet,Courtney D. DiNardo,Abhishek Maiti,Gautam Borthakur,Naval G. Daver,Nicholas J. Short,Elias J. Jabbour,Ghayas C. Issa,Naveen Pemmaraju,Musa Yilmaz,Guillermo Montalban-Bravo,Koichi Takahashi,Sanam Loghavi,Guillermo Garcia-Manero,Farhad Ravandi,Hagop M. Kantarjian,Tapan M. Kadia
View Articletitled, Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia
Ramanagouda Ramanagoudr-Bhojappa,Rebecca Tryon,Francis P. Lach,Frank X. Donovan,Rochelle Maxwell,Allana Rosenberg,Margaret L. MacMillan,John E. Wagner,Arleen D. Auerbach,Agata Smogorzewska,Settara C. Chandrasekharappa
View Articletitled, <em>FANCA</em> c.3624C&gt;T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia
Supplemental data
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel
Deva Sharma,Ilknur Kozanoğlu,Kenneth I. Ataga,Alexandra Benachi,Selim Büyükkurt,Sophie Lanzkron,Hakan Ozdogu,Shivan Pancham,Lydia H. Pecker,Susan E. Robinson,Safak Yilmaz Baran,Jo Howard
View Articletitled, Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel
Supplemental data

THROMBOSIS AND HEMOSTASIS

A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation
Romy M. W. de Laat-Kremers,Denis Wahl,Stéphane Zuily,Marisa Ninivaggi,Véronique Regnault,Jacek Musial,Philip G. de Groot,Katrien M. J. Devreese,Bas de Laat
View Articletitled, A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation
Supplemental data

TRANSPLANTATION

CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model
Lotus Neidemire-Colley,Shrijan Khanal,Kara M. Braunreiter,Yandi Gao,Rathan Kumar,Katiri J. Snyder,Margot A. Weber,Simran Surana,Olimjon Toirov,Malith Karunasiri,Molly E. Duszynski,Mengna Chi,Punam Malik,Sonu Kalyan,Wing K. Chan,Meisam Naeimi Kararoudi,Hannah K. Choe,Ramiro Garzon,Parvathi Ranganathan
View Articletitled, CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model
Supplemental data
Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients
Matt S. Zinter,Ruta Brazauskas,Joelle Strom,Stella Chen,Stephanie Bo-Subait,Akshay Sharma,Amer Beitinjaneh,Dimana Dimitrova,Greg Guilcher,Jaime Preussler,Kasiani Myers,Neel S. Bhatt,Olle Ringden,Peiman Hematti,Robert J. Hayashi,Sagar Patel,Satiro Nakamura De Oliveira,Seth Rotz,Sherif M. Badawy,Taiga Nishihori,David Buchbinder,Betty Hamilton,Bipin Savani,Hélène Schoemans,Mohamed Sorror,Lena Winestone,Christine Duncan,Rachel Phelan,Christopher C. Dvorak
View Articletitled, Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients
Supplemental data

VASCULAR BIOLOGY

Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice
Lulu Huang,Yuji Kondo,Lijuan Cao,Jingjing Han,Tianyi Li,Bin Zuo,Fei Yang,Yun Li,Zhenni Ma,Xia Bai,Miao Jiang,Changgeng Ruan,Lijun Xia
View Articletitled, Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice
Supplemental data

RESEARCH LETTERS

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Clinical Trials & Observations
Marco Herling,Claire Dearden,Francesco Zaja,Dima El-Sharkawi,Wei Ding,Mar Bellido,Amit Khot,Lidwine Tick,Eric Jacobsen,Toby A. Eyre,Damien Roos-Weil,Tapan Kadia,Elisa Lucchini,Natali Pflug,Matthew S. Davids,German Pena,Nabanita Mukherjee,Mohamed Badawi,Tamas Vizkelety,Philipp B. Staber
View Articletitled, Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Supplemental data
A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML
Clinical Trials & Observations
Zhibo Zhang,Jia Yin,Guoli Lian,Xiebing Bao,Meng Hu,Zhenfang Liu,Yuan Yu,Ruihua Mi,Yabei Zuo,Pengcheng Shi,Weiyan Zheng,Qian Jiang,Hongying Chao,Peifang Xiao,Weijuan Yu,Yanqiu Han,Yu Wu,Yan Zeng,Depei Wu,Xiaofei Yang,Suning Chen
View Articletitled, A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and <em>KIT</em> mutant t(8;21) AML
Supplemental data
Estimation of eligibility for and response to CAR-T therapy in the United States
Alyson Haslam,Tracy Beth Hoeg,Vinay Prasad
View Articletitled, Estimation of eligibility for and response to CAR-T therapy in the United States
Maybe you can’t drive this CAR?
Benjamin A. Derman
View Articletitled, Maybe you can’t drive this CAR?
Survival in Agent Orange exposed and unexposed Vietnam-era veterans who were diagnosed with lymphoid malignancies
Helen Ma,Jia Y. Wan,Victoria K. Cortessis,Pankaj Gupta,Wendy Cozen
View Articletitled, Survival in Agent Orange exposed and unexposed Vietnam-era veterans who were diagnosed with lymphoid malignancies
Supplemental data

COMMENTARY

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
Clinical Trials & Observations
Rahul Banerjee,Christina Poh,Alexandre V. Hirayama,Jordan Gauthier,Ryan D. Cassaday,Mazyar Shadman,Andrew J. Cowan,Brian G. Till,Damian J. Green,Hans-Peter Kiem,Ajay K. Gopal,David G. Maloney
View Articletitled, Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic

ERRATUM

Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266-6274.
View Articletitled, Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. <em>Blood Adv.</em> 2023;7(20):6266-6274.
  • Cover Image

    Cover Image

    issue cover

    NOD/SCID/IL2rγnull (NSG) mice were irradiated (100 cGy) and transplanted with control T cells or CRISPR/Cas9–edited MIR155HGΔexon3 human T cells. Hematoxylin and eosin staining show control human T-cell infiltration (purple) in a skin section from a recipient mouse with acute graft-versus-host disease (GVHD). NSG mice that received MIR155HGΔexon3 human T cells exhibit reduced T-cell infiltration in target organs and are protected from lethal GVHD. See the article by Neidemire-Colley et al.

All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals